Purpose PET/CT with both 11C-choline and 11C-methionine has recently been reported to offer advantages over 18F-FDG for imaging in multiple myeloma (MM). The aim of this study was to directly compare the diagnostic performance of both non-FDG radiotracers in MM patients. Methods Nineteen patients with a history of MM (n = 18) or solitary bone plasmacytoma (n = 1) underwent both 11C-choline and 11C-methionine PET/CT for diagnostic imaging. In this retrospective analysis, scans were compared on a patient and on a lesion basis. In 12 patients, respective tracer uptake in the iliac crest was correlated with the extent of malignant bone marrow plasma cell infiltration. Results 11C-methionine detected more intramedullary MM lesions in 8 (42.1%) of 19 patients. In the remainder (11/19 [57.9%]), both 11C-choline and 11C-methionine provided equal results. 11C-methionine demonstrated higher lesion-to-muscle ratios (P = 0.0001). In the 12 patients in whom a recent bone marrow biopsy was available, SUVmean as well as SUVmax correlated significantly with the degree of malignant plasma cell infiltration for both 11C-methionine (SUVmean: r = 0.85, P < 0.001; SUVmax: r = 0.82, P = 0.001) and 11C-choline (SUVmean: r = 0.72, P < 0.008; SUVmax: r = 0.73; P = 0.006). Conclusions Our data suggest that 11C-methionine PET/CT might be more sensitive than 11C-choline PET/CT for the detection of active MM lesions.
Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma / C. Lapa, M. Kircher, M.C. Da Via, M. Schreder, L. Rasche, K.M. Kortum, H. Einsele, A.K. Buck, H. Hanscheid, S. Samnick. - In: CLINICAL NUCLEAR MEDICINE. - ISSN 0363-9762. - 44:8(2019 Aug), pp. 620-624. [10.1097/RLU.0000000000002638]
Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma
M.C. Da ViaSecondo
;
2019
Abstract
Purpose PET/CT with both 11C-choline and 11C-methionine has recently been reported to offer advantages over 18F-FDG for imaging in multiple myeloma (MM). The aim of this study was to directly compare the diagnostic performance of both non-FDG radiotracers in MM patients. Methods Nineteen patients with a history of MM (n = 18) or solitary bone plasmacytoma (n = 1) underwent both 11C-choline and 11C-methionine PET/CT for diagnostic imaging. In this retrospective analysis, scans were compared on a patient and on a lesion basis. In 12 patients, respective tracer uptake in the iliac crest was correlated with the extent of malignant bone marrow plasma cell infiltration. Results 11C-methionine detected more intramedullary MM lesions in 8 (42.1%) of 19 patients. In the remainder (11/19 [57.9%]), both 11C-choline and 11C-methionine provided equal results. 11C-methionine demonstrated higher lesion-to-muscle ratios (P = 0.0001). In the 12 patients in whom a recent bone marrow biopsy was available, SUVmean as well as SUVmax correlated significantly with the degree of malignant plasma cell infiltration for both 11C-methionine (SUVmean: r = 0.85, P < 0.001; SUVmax: r = 0.82, P = 0.001) and 11C-choline (SUVmean: r = 0.72, P < 0.008; SUVmax: r = 0.73; P = 0.006). Conclusions Our data suggest that 11C-methionine PET/CT might be more sensitive than 11C-choline PET/CT for the detection of active MM lesions.File | Dimensione | Formato | |
---|---|---|---|
lapa2019.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
760.11 kB
Formato
Adobe PDF
|
760.11 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.